RA CAPITAL MANAGEMENT, L.P.
Transaction: 01/07/2026
SELL
Change
-1,286,786
Price
$0.00
Filing
01/09/2026
Type
SELL
Cidara Therapeutics, Inc.
CDTX • Biotechnology
$221.38
— 0.00 (0.00%)
Current price
EarningsLatest report: Sep 30, 2025
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$3.44B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Healthy liquidity · 4.25Negative growth trendWeak profitability
Financial data as of: Sep 30, 2025, 12:00 AM UTCLast earnings update: Nov 6, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$221.38
Change0.00%
Shares Out15.55M
Market Cap$3.44B
Enterprise Value$3.15B
52W Range15.22 - 221.42
Beta1.53
P/E-18.63
P/B8.15
P/FCF-25.89
EV/EBITDA-16.59
EV/FCF-23.70
Price$221.38
Change0.00%
Shares Out15.55M
Market Cap$3.44B
Enterprise Value$3.15B
52W Range15.22 - 221.42
Beta1.53
P/E-18.63
P/B8.15
P/FCF-25.89
EV/EBITDA-16.59
EV/FCF-23.70
Earnings Yield-5.37%
FCF Yield-3.86%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-138.12%
Profit Margin-133.20%
Debt/Eq0.02
Current Ratio4.25
Quick Ratio4.25
Target$177.88
Target Upside-19.65%
Target Median$170.00
Target Range150.00 - 221.50
Volume2.69M
Avg Volume1.37M
EPS Surprise-0.09
Investment DNA
How strong this company looks for long-term investors
38
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
70/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 4.25Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 11 analyst votes · 2026-09-05
86/100
Bullish
Bullish
8
Hold
3
Bearish
0
Price Target
2026-06-05
Low
$150.00
Mean
$177.88
Median
$170.00
High
$221.50
Insider Transactions
Recent executive and insider activity
⚠ 3 high-volume insider sells detected
RA CAPITAL MANAGEMENT, L.P.
Transaction: 01/07/2026
SELL
Change
-22,200
Price
$26.62
Filing
01/09/2026
Type
SELL
RA CAPITAL MANAGEMENT, L.P.
Transaction: 01/07/2026
SELL
Change
-89,956
Price
Not reported
Filing
01/09/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | SELL | -1,286,786 | $0.00 | 01/07/2026 | 01/09/2026 |
| RA CAPITAL MANAGEMENT, L.P. | SELL | -22,200 | $26.62 | 01/07/2026 | 01/09/2026 |
| RA CAPITAL MANAGEMENT, L.P. | SELL | -89,956 | Not reported | 01/07/2026 | 01/09/2026 |
| RA CAPITAL MANAGEMENT, L.P. | SELL | -4,652,309 | $221.50 | 01/07/2026 | 01/09/2026 |
| Davarpanah Nicole Negar | SELL | -62,597 | $10.75 | 01/07/2026 | 01/07/2026 |
| Davarpanah Nicole Negar | SELL | -8,333 | $221.50 | 01/07/2026 | 01/07/2026 |
| Ward Shane | SELL | -25,083 | $221.50 | 01/07/2026 | 01/07/2026 |
| Ward Shane | SELL | -6,207 | $20.20 | 01/07/2026 | 01/07/2026 |
| KARBE FRANK | SELL | -115,000 | $20.50 | 01/07/2026 | 01/07/2026 |
| KARBE FRANK | SELL | -43,125 | $221.50 | 01/07/2026 | 01/07/2026 |
| Stein Jeffrey | SELL | -67,498 | $221.50 | 01/07/2026 | 01/07/2026 |
| Stein Jeffrey | SELL | -27,174 | $20.20 | 01/07/2026 | 01/07/2026 |
| BURGESS DANIEL D | SELL | -150 | $221.50 | 01/07/2026 | 01/07/2026 |
| BURGESS DANIEL D | SELL | -875 | $79.40 | 01/07/2026 | 01/07/2026 |
| Schroeder Theodore R | SELL | -450 | $204.40 | 01/07/2026 | 01/07/2026 |
| Mineo Chrysa | SELL | -1,400 | $10.60 | 01/07/2026 | 01/07/2026 |
| Mineo Chrysa | SELL | -3,320 | $221.50 | 01/07/2026 | 01/07/2026 |
| Bassler Bonnie L | SELL | -15 | $221.50 | 01/07/2026 | 01/07/2026 |
| Bassler Bonnie L | SELL | -1,750 | $50.20 | 01/07/2026 | 01/07/2026 |
| Canale-Theakston Carin | SELL | -875 | $38.40 | 01/07/2026 | 01/07/2026 |